Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment… Read more
Axsome Therapeutics Inc (AXSM) - Net Assets
Latest net assets as of December 2025: $88.30 Million USD
Based on the latest financial reports, Axsome Therapeutics Inc (AXSM) has net assets worth $88.30 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($689.80 Million) and total liabilities ($601.51 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $88.30 Million |
| % of Total Assets | 12.8% |
| Annual Growth Rate | N/A |
| 5-Year Change | 464.89% |
| 10-Year Change | 309.31% |
| Growth Volatility | 5677.67 |
Axsome Therapeutics Inc - Net Assets Trend (2013–2025)
This chart illustrates how Axsome Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Axsome Therapeutics Inc (2013–2025)
The table below shows the annual net assets of Axsome Therapeutics Inc from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $88.30 Million | +54.86% |
| 2024-12-31 | $57.02 Million | -70.15% |
| 2023-12-31 | $190.98 Million | +74.32% |
| 2022-12-31 | $109.56 Million | +600.92% |
| 2021-12-31 | $15.63 Million | -86.26% |
| 2020-12-31 | $113.79 Million | -36.33% |
| 2019-12-31 | $178.72 Million | +18955.16% |
| 2018-12-31 | $937.92K | -94.39% |
| 2017-12-31 | $16.72 Million | -22.50% |
| 2016-12-31 | $21.57 Million | -53.55% |
| 2015-12-31 | $46.44 Million | +1550.22% |
| 2014-12-31 | $-3.20 Million | -57.93% |
| 2013-12-31 | $-2.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axsome Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130373234300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $5.00K | 0.01% |
| Other Components | $1.39 Billion | 1579.08% |
| Total Equity | $88.30 Million | 100.00% |
Axsome Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Axsome Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Molina Healthcare Inc
NYSE:MOH
|
$6.97 Billion |
|
TongFu Microelectronics Co Ltd
SHE:002156
|
$6.97 Billion |
|
Bangkok Bank Public Company Limited
PINK:BKKPF
|
$6.97 Billion |
|
Canadian Western Bank
PINK:CWESF
|
$6.98 Billion |
|
Nedbank Group Limited
PINK:NDBKF
|
$6.96 Billion |
|
Powerchip Semiconductor Manufacturing Corp.
TW:6770
|
$6.96 Billion |
|
SCB X Public Company Limited
BK:SCB
|
$6.95 Billion |
|
Sonic Healthcare Limited
PINK:SKHCF
|
$6.95 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axsome Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 57,015,000 to 88,295,000, a change of 31,280,000 (54.9%).
- Net loss of 183,174,000 reduced equity.
- New share issuances of 67,904,000 increased equity.
- Other factors increased equity by 146,550,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-183.17 Million | -207.46% |
| Share Issuances | $67.90 Million | +76.91% |
| Other Changes | $146.55 Million | +165.98% |
| Total Change | $- | 54.86% |
Book Value vs Market Value Analysis
This analysis compares Axsome Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 90.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.26 | $161.17 | x |
| 2014-12-31 | $-0.25 | $161.17 | x |
| 2015-12-31 | $3.89 | $161.17 | x |
| 2016-12-31 | $1.13 | $161.17 | x |
| 2017-12-31 | $0.73 | $161.17 | x |
| 2018-12-31 | $0.03 | $161.17 | x |
| 2019-12-31 | $-5.17 | $161.17 | x |
| 2020-12-31 | $3.06 | $161.17 | x |
| 2021-12-31 | $0.42 | $161.17 | x |
| 2022-12-31 | $2.69 | $161.17 | x |
| 2023-12-31 | $4.20 | $161.17 | x |
| 2024-12-31 | $1.19 | $161.17 | x |
| 2025-12-31 | $1.77 | $161.17 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axsome Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -207.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -28.69%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 7.81x
- Recent ROE (-207.46%) is above the historical average (-429.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.96 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.68 Million |
| 2015 | -26.29% | 0.00% | 0.00x | 1.06x | $-16.86 Million |
| 2016 | -126.10% | 0.00% | 0.00x | 1.77x | $-29.36 Million |
| 2017 | -173.14% | 0.00% | 0.00x | 2.13x | $-30.62 Million |
| 2018 | -3301.50% | 0.00% | 0.00x | 16.40x | $-31.06 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-50.76 Million |
| 2020 | -90.43% | 0.00% | 0.00x | 1.64x | $-114.28 Million |
| 2021 | -863.34% | -1530.01% | 0.10x | 5.62x | $-136.51 Million |
| 2022 | -170.81% | -373.99% | 0.15x | 3.03x | $-198.09 Million |
| 2023 | -125.27% | -88.41% | 0.46x | 3.08x | $-258.34 Million |
| 2024 | -503.76% | -74.47% | 0.68x | 9.97x | $-292.92 Million |
| 2025 | -207.46% | -28.69% | 0.93x | 7.81x | $-192.00 Million |
Industry Comparison
This section compares Axsome Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axsome Therapeutics Inc (AXSM) | $88.30 Million | 0.00% | 6.81x | $6.97 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |